Conversations with the Life Raft Group will debuted 4/2/2020 at 1 pm. Our first featured guest was Norman J. Scherzer, the Executive Director of the Life Raft Group. With his background at the CDC as Assistant Commissioner of Health for NYC, Norman is an excellent resource for discussing strategies for coping with COVID-19.
During this webcast presentation, Dr. Michael Heinrich will discuss these two new treatment options for advanced GIST. Dr. Heinrich will explain how each of these drugs works to target mutations for which there has previously been no targeted treatment and discuss the current coronavirus outbreak.
This webinar teaches the basics of The Life Raft Group's new software, GIST CHAT, which will replace our patient ListServ.
Dr. Nikhil Guhagarkar discusses the dental and oral complications of drugs used in GIST treatment and treatment of these side effects.
Dr. Jason Sicklick of Moores Cancer Center at the University of California San Diego talks about the Phase II study of Temozolomide (TMZ) in advanced SDH-mutant/deficient GIST, a new study available to patients with SDH-deficient GIST.
Kathy Sarmiento presents, The A B C’s of Medicare: Everything you need to know. Kathy explains everything from medicare costs and eligibility, to finding the right path for you.
Blueprint Medicines hosted a webinar for the GIST patient and caregiver community about Avapritinib, an investigational medicine for people with advanced GIST.
Medicare 101: An Overview of the A, B, C, and Ds of Medicare The A B C’s of Medicare: Everything you need to know What is Medicare, am I eligible and how do I enroll? [...]
This webcast was originally recorded May 21, 2019. Follow this link for webcast with Hebrew Subtitles. Listen to the webcast - Hebrew subtitles Are you interested in optimizing your treatment? In [...]
Most GIST patients will see a surgeon at some point during their treatment. This webcast will address the issues surrounding the decision to have an operation and considers that surgical options depend on a number of factors such as tumor location, tumor size, tumor number, response to drug therapy, and risk of recurrence.